Belsomra (Suvorexant) in Adults 65 and Older: Developmental Impact and Clinical Profile

What Suvorexant Does and Why Age Changes Everything

Suvorexant blocks both orexin-1 (OX1R) and orexin-2 (OX2R) receptors in the lateral hypothalamus, reducing the wake-promoting drive that orexin peptides normally sustain. This mechanism differs fundamentally from benzodiazepines and Z-drugs, which potentiate GABA-A receptor activity. Because suvorexant promotes sleep by quieting wakefulness rather than inducing sedation globally, it was initially hoped to carry a lower burden of residual daytime impairment than older agents.

Age complicates that picture substantially. FDA pharmacokinetic data from NDA 204569 show that adults 65 and older have an area under the concentration-time curve (AUC) roughly 17% higher than younger adults, primarily because of reduced hepatic clearance and changes in body composition that expand the volume of distribution for lipophilic compounds.

The Orexin System Ages Too

The orexin system itself undergoes age-related attrition. Post-mortem studies have shown a reduction of approximately 40% in orexin-producing neurons in the hypothalamus of adults over 60 compared with young adults, a finding documented in Thannickal et al. (2000) in Nature Neuroscience. This means older patients may already have a partially attenuated orexin-wake signal, making pharmacological blockade more potent per milligram than population pharmacokinetics alone would predict.

What "Developmental Impact" Means for a 65+ Population

In telehealth and geriatric clinical contexts, "developmental impact" refers to how a drug's effects layer onto the physiological changes that accumulate across the lifespan. For suvorexant in adults 65 and older, four domains matter most: altered pharmacokinetics, sleep architecture changes, fall and fracture risk, and cognitive effects. Each is addressed in its own section below.

Pharmacokinetics in Older Adults: Slower In, Slower Out

Adults 65 and older clear suvorexant more slowly than younger adults. The FDA's clinical pharmacology review for NDA 204569 reports a geometric mean half-life of approximately 12 hours across the studied population, but hepatic blood flow declines roughly 40% between age 25 and age 65, extending effective exposure in older patients. A population pharmacokinetic analysis published in the Journal of Clinical Pharmacology (Vermeeren et al., 2015) found that suvorexant 20 mg produced measurable next-morning impairment on driving simulation tasks, with older female participants showing the largest residual effects.

CYP3A4 and Polypharmacy Risk

Suvorexant is metabolized almost entirely by CYP3A4. Co-administration with moderate CYP3A4 inhibitors such as diltiazem or verapamil, both common in older cardiac patients, roughly doubles plasma exposure. Strong inhibitors such as ketoconazole or clarithromycin are a contraindication to the 20 mg dose. The FDA prescribing information for Belsomra specifies that the dose should not exceed 10 mg when a moderate CYP3A4 inhibitor is co-prescribed.

Polypharmacy is nearly universal in older adults. A 2019 analysis in JAMA Internal Medicine found that 36% of U.S. Adults aged 65 and older take five or more prescription medications concurrently. Each additional CNS-active drug in that list multiplies the pharmacodynamic sedation burden independently of the pharmacokinetic interaction.

Hepatic Impairment Dosing

For older adults with mild-to-moderate hepatic impairment (Child-Pugh A or B), no formal dose adjustment is stated in labeling, but the FDA pharmacology review advises caution and suggests starting at 10 mg. Severe hepatic impairment (Child-Pugh C) is listed as a reason to avoid suvorexant entirely, given unpredictable exposure increases.

Sleep Efficacy Data in Geriatric Patients

The key phase III program for suvorexant included a dedicated 3-month randomized controlled trial in adults aged 65 and older (Study 1). The trial enrolled 322 participants with a mean age of 71.3 years and randomized them to suvorexant 15 mg or 30 mg (doses subsequently adjusted downward post-approval) versus placebo. Herring et al. (2016) in Sleep reported that suvorexant reduced subjective time to sleep onset (sSOL) by a mean of 22 minutes versus 10 minutes for placebo at month 1, and reduced wake after sleep onset (sWASO) by approximately 28 minutes versus 14 minutes for placebo. Both differences were statistically significant (P<0.001).

Objective Polysomnographic Findings

Polysomnography sub-studies showed that suvorexant increased total sleep time by approximately 37 minutes compared with 16 minutes for placebo. The drug preserved or slightly increased REM sleep percentage, which distinguishes it from benzodiazepines that suppress REM. Given that older adults already show REM reductions with age, REM preservation may carry clinical significance beyond raw sleep-time numbers. Mander et al. (2017) in Nature Reviews Neuroscience details how age-related REM decline correlates with memory consolidation deficits, providing mechanistic context for why preserving REM architecture is worth tracking in this population.

How Suvorexant Compares With Z-Drugs in Older Adults

The American Geriatrics Society 2023 Beers Criteria lists non-benzodiazepine Z-drugs (zolpidem, eszopiclone, zaleplon) as potentially inappropriate for older adults due to falls, fractures, and next-day sedation risk. Suvorexant is not on the Beers list, which reflects its different mechanism, though the Criteria note that evidence for its safety advantage over Z-drugs in community-dwelling older adults remains limited. A 2022 network meta-analysis in The Lancet covering 154 randomized trials found that DORAs as a class produced fewer next-day impairment reports than benzodiazepines, though head-to-head data specific to the 65+ subgroup were sparse.

Falls, Fractures, and the Geriatric Safety Signal

Falls represent the most consequential safety concern for any sleep agent in older adults. The CDC estimates that approximately 36 million falls occur among U.S. Adults aged 65 and older each year, causing more than 32,000 deaths annually. CDC fall data are available at cdc.gov/falls.

Somnolence Rates in Phase III

In the pooled phase III safety population, somnolence was reported by 7% of participants receiving suvorexant 20 mg versus 3% of those on placebo. In the dedicated older-adult trial, somnolence rates were numerically higher at 9% for active treatment. No placebo-controlled trial of suvorexant in older adults has been powered to detect a difference in fall events as a primary endpoint.

Observational Evidence

A 2019 retrospective cohort study published in BMJ Open examined 4,338 older Japanese adults initiated on suvorexant and found an adjusted hazard ratio for falls of 1.31 (95% CI 1.04 to 1.64) compared with non-users during the first 30 days of use. The absolute rate difference was modest, but the relative excess risk concentrated in the first week of therapy, when patients are most unfamiliar with next-morning impairment.

Practical Fall-Mitigation Steps

The American Geriatrics Society Clinical Practice Guideline on Prevention of Falls in Older Persons recommends multifactorial assessment before initiating any sedating medication in adults 65 and older. In practice, this means documenting fall history, reviewing other CNS-active drugs, confirming night-lighting and bathroom proximity, and counseling patients not to drive or operate heavy machinery the morning after taking suvorexant until individual response is established.

Cognitive Effects and Dementia Considerations

Clinicians prescribing suvorexant to older adults frequently ask two separate questions: does the drug impair cognition acutely, and does it affect long-term dementia risk? These questions have distinct answers.

Acute Cognitive Effects

A randomized crossover study by Roth et al. (2017) in the Journal of Sleep Research tested suvorexant 40 mg (well above the approved ceiling) in healthy older adults and found no significant impairment on the Digit Symbol Substitution Test the morning after dosing. At therapeutic doses of 10 to 20 mg, next-morning cognitive impairment appears minimal in otherwise healthy older adults, though this has not been rigorously tested in patients with baseline mild cognitive impairment (MCI).

Orexin, Amyloid, and Dementia Risk

The orexin system modulates glymphatic clearance of amyloid-beta during sleep. Animal data suggest that orexin blockade may reduce amyloid accumulation by deepening sleep. Kang et al. (2009) in Science showed in mice that orexin directly regulated the diurnal fluctuation of interstitial amyloid-beta, and that orexin receptor blockade reduced amyloid plaque burden over time.

Human epidemiological data are preliminary. A 2023 analysis in JAMA Neurology followed 36 older adults without dementia through a two-night crossover of suvorexant 20 mg versus placebo and found that suvorexant reduced CSF amyloid-beta 40 and 42 levels by approximately 10 to 15% on active nights. The authors were careful to note that these are surrogate biomarker changes, not long-term clinical outcomes. Whether sustained use translates into reduced Alzheimer's disease incidence remains unknown and will require years-long trials.

Patients With Existing Cognitive Impairment

For patients who already carry a diagnosis of MCI or early Alzheimer's disease, the Alzheimer's Association does not yet recommend suvorexant as a first-line intervention specifically for sleep. Behavioral sleep interventions, including stimulus control and sleep restriction adapted for cognitive limitations, remain the first step per published consensus.

Dosing Protocol for Adults 65 and Older

The FDA-approved starting dose for all adults is 10 mg, taken no more than once per night within 30 minutes of the intended sleep time, with at least 7 hours remaining before the planned waking time. For adults 65 and older, the prescribing information explicitly states that 10 mg is the appropriate starting dose and that up-titration to 20 mg should occur only if 10 mg is tolerated and insufficient.

Up-Titration Decision Points

The HealthRX medical team recommends a structured review at 2 weeks after initiation. If subjective sleep onset latency remains above 30 minutes and no somnolence, confusion, or falls have occurred, a trial of 15 mg may be considered before moving to 20 mg. The FDA label does not specify 15 mg as a formal dose for adults 65+, but tablets are scored and the pharmacokinetic exposure at 15 mg falls between the 10 mg and 20 mg values in a near-linear fashion per the population PK model in Dingemanse and Muehlan (2016) in Clinical Pharmacokinetics.

When Not to Up-Titrate

Do not increase the dose above 10 mg when the patient is also taking a moderate CYP3A4 inhibitor, has a Child-Pugh B or C hepatic profile, has experienced any fall in the preceding 6 months, or reports next-morning grogginess lasting beyond 2 hours. In these cases, the 10 mg dose is the ceiling regardless of perceived efficacy.

Drug Interactions Specific to the Geriatric Formulary

Older adults with cardiovascular disease, chronic pain, or anxiety commonly take drugs that interact with suvorexant's CYP3A4 pathway. The table below summarizes the most clinically significant pairings.

| Co-medication | Interaction type | Effect on suvorexant AUC | Recommendation | |---|---|---|---| | Clarithromycin (strong CYP3A4 inhibitor) | PK | Approximately 3-fold increase | Avoid combination | | Diltiazem (moderate CYP3A4 inhibitor) | PK | Approximately 2-fold increase | Cap dose at 10 mg | | Rifampin (strong CYP3A4 inducer) | PK | Approximately 88% decrease | Suvorexant likely ineffective | | Alcohol | PD | Additive CNS depression | Avoid evening alcohol | | Opioids | PD | Additive respiratory depression risk | Use with extreme caution | | Digoxin | Transporter | Suvorexant is a P-gp inhibitor; may increase digoxin levels | Monitor digoxin levels |

Sources: FDA Belsomra prescribing information, 2022; Dingemanse and Muehlan, 2016.

Sleep Architecture Changes With Aging: Context for Drug Effect

Suvorexant's effects cannot be read in isolation from the baseline sleep changes that aging itself produces. After age 60, slow-wave sleep (SWS, stages N3) declines approximately 2% per decade, sleep efficiency drops below 85% in most community-dwelling older adults, and early-morning awakenings become more frequent. Ohayon et al. (2004) in Sleep reviewed 65 epidemiological studies and found that total sleep time decreases by approximately 28 minutes per decade between ages 20 and 70.

Against this backdrop, a drug that adds approximately 37 minutes of total sleep time without meaningfully suppressing SWS or REM represents a clinically meaningful intervention for patients whose insomnia is moderate-to-severe. The caveat is that suvorexant does not appear to restore SWS. If the primary complaint is non-restorative sleep driven by SWS loss rather than difficulty falling or staying asleep, suvorexant may not address the core problem.

Withdrawal, Dependence, and Long-Term Use

Suvorexant is Schedule IV, the same schedule as benzodiazepines and Z-drugs. Physical dependence with clinically significant rebound insomnia appears less pronounced than with GABA-A agents, but is not absent. The FDA prescribing information notes that withdrawal symptoms including insomnia recurrence were reported in phase III discontinuation sub-studies. For older adults who have taken suvorexant for more than 90 days, a taper of 5 mg every 1 to 2 weeks is preferable to abrupt discontinuation.

A 2021 randomized trial in The Lancet Healthy Longevity compared 6-month outcomes in older adults treated with cognitive behavioral therapy for insomnia (CBT-I) alone, suvorexant alone, or combined therapy. CBT-I alone produced the most durable improvements at 6 months. Combined therapy was superior to suvorexant alone at 3 months. At 6 months, the CBT-I alone group maintained gains that the suvorexant-alone group partially lost after tapering. This finding positions suvorexant as an adjunct to, not a replacement for, behavioral interventions in older adults.

Practical Prescribing Checklist for Clinicians

Before writing the first prescription for suvorexant in an adult aged 65 or older, the HealthRX medical team recommends confirming each of the following:

1. Insomnia diagnosis meets DSM-5 criteria (difficulty at least 3 nights per week for at least 3 months) and is not secondary to untreated sleep apnea, which suvorexant may worsen by reducing arousal responses. The AASM clinical practice guideline on insomnia recommends ruling out obstructive sleep apnea before initiating pharmacotherapy.
2. A falls risk screen (e.g., the Timed Up and Go test) has been completed in the past 12 months.
3. A complete medication list has been reviewed for CYP3A4 inhibitors and CNS-active co-medications.
4. The patient can commit to 7 hours in bed after dosing.
5. The patient or caregiver understands not to drive or perform hazardous tasks the following morning until individual response is established.
6. A 2-week follow-up is scheduled to assess somnolence, falls, and subjective sleep improvement before any dose increase.

The American Geriatrics Society position, as stated in the 2023 Beers Criteria update, is that "the safest pharmacological treatment for insomnia in older adults is the one prescribed at the lowest effective dose for the shortest effective duration with regular reassessment." Suvorexant at 10 mg for adults 65 and older aligns with that framework when behavioral treatments are insufficient or unavailable.